Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.

Four new series of 2,4'-bis diphenylamine hydrazones 14, 2,4'-bis aminothiadiazole 16, 2,4'-bis mercaptotriazole 17-18 and 2,4'-bis mercapto-oxadiazole diphenylamine derivatives 19-20 were synthesized and evaluated for their ability to inhibit EGFR tyrosine kinase. Compound N-ethyl-5-{2-[4-(5-(ethylamino)-1,3,4-thiadiazol-2-yl)- phenylamino]phenyl}-1,3,4-thiadiazol-2-amine 16a was the most active enzyme inhibitor (98% inhibition at 10 microM). Moreover, all compounds that showed enzyme inhibition activity were tested in vitro on human breast carcinoma cell line (MCF-7) in which EGFR is highly expressed. The tested compounds exploited potent antitumor activity with IC(50) values ranging 0.73-2.38 microM. Molecular modeling and docking of the synthesized compounds into the active site of EGFR kinase domain showed good agreement with the obtained biological results. The present work represents a novel class of diphenylamine based derivatives with potent cytotoxicity and promising EGFR PTK inhibition activity.

[1]  Mary Adams,et al.  4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[2]  J. D. de Bono,et al.  Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). , 2007, European journal of cancer.

[3]  W. Rzeski,et al.  Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound. , 2007, Bioorganic & medicinal chemistry.

[4]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[5]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[6]  A. B. S. Juan.  Towards predictive inhibitor design for the EGFR autophosphorylation activity , 2008 .

[7]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[8]  A. Demirbaş,et al.  Synthesis of 3-alkyl(aryl)-4-alkylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-ones and 3-alkyl-4-alkylamino-4,5-dihydro-1H-1,2,4-triazol-5-ones as antitumor agents. , 2002, Bioorganic & medicinal chemistry.

[9]  W. Denny,et al.  Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. , 1995, Journal of medicinal chemistry.

[10]  W. Denny.  The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. , 2001, Farmaco.

[11]  R. Nilakantan,et al.  6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. , 2001, Journal of medicinal chemistry.

[12]  Xiao-min Luo,et al.  Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. , 2005, Bioorganic & medicinal chemistry.

[13]  P. Traxler,et al.  Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. , 1999, Journal of medicinal chemistry.

[14]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[15]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. , 2004, European journal of medicinal chemistry.

[17]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[18]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[19]  Toshiyuki Shimizu,et al.  Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[20]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[21]  K. Lackey,et al.  Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. , 2003, Bioorganic & medicinal chemistry letters.

[22]  B. Song,et al.  Synthesis, structure, and bioactivity of N'-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives. , 2006, Bioorganic & medicinal chemistry letters.

[23]  Mary Adams,et al.  Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. , 2008, Bioorganic & medicinal chemistry letters.

[24]  P. Furet,et al.  Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. , 2004, European journal of medicinal chemistry.

[25]  N. Heindel,et al.  Improved syntheses of 5‐substituted‐4‐amino‐3‐mercapto‐(4H)‐1,2,4‐triazoles , 1976 .

[26]  K. Abouzid,et al.  Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. , 2008, Bioorganic & medicinal chemistry.

[27]  J. Kauffman,et al.  Synthesis and structure-activity relationships of anti-inflammatory 9,10-dihydro-9-oxo-2-acridine-alkanoic acids and 4-(2-carboxyphenyl)aminobenzenealkanoic acids. , 1990, Journal of pharmaceutical sciences.

[28]  W. Denny,et al.  Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. , 1996, Journal of medicinal chemistry.

[29]  W. Denny,et al.  Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. , 1997, Journal of medicinal chemistry.

[30]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.